Education
About Us
Working with TipRanks
Follow Us
Edgewise Therapeutics (EWTX)
NASDAQ:EWTX
EWTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$14.90 - $38.12
Previous CloseN/A
Volume107.81K
Average Volume (3M)1.35M
Market Cap
$2.25B
Enterprise Value$2.02B
Total Cash (Recent Filing)$41.67M
Total Debt (Recent Filing)$4.74M
Price to Earnings (P/E)―
Beta1.66
Next Earnings
May 08, 2025EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.45
Shares Outstanding95,205,284
10 Day Avg. Volume1,701,204
30 Day Avg. Volume1,345,861
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-20.90
P/FCF Ratio0.00
Enterprise Value/Market Cap0.90
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-12.69
Forecast
1Y Price Target
$47.13Price Target Upside99.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
---
Edgewise Therapeutics News
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe GRAND CANYON enrollment was completed with 175 adults, much higher than the target enrollment, which bodes well for powering.
Regulatory ApprovalEWTX announced that the Phase 2 CANYON study of sevasemten in Becker muscular dystrophy met the primary endpoint of creatine kinase reduction, and key secondaries showed trends towards improvement, hitting their goals for the study.
Safety DataInitial safety data for EDG-7500 look encouraging, with no LVEF<50% cases.
Bears Say
Clinical Data ChallengesThere are significant NSAA baseline imbalances in the sevasemten ph2 BMD data, making it hard to have real conviction that these data support accelerated approval.
Market PerceptionInvestors may be a little frustrated that the LYNX/FOX readout keeps getting pushed out.
Regulatory ChallengesThe window to clearly differentiate from aficamten is narrow, and the path to doing so is tricky with high regulatory bar.
---
Ownership Overview
31.71% Insiders
11.78% Mutual Funds
<0.01% Other Institutional Investors
47.05% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EWTX FAQ
What was Edgewise Therapeutics’s price range in the past 12 months?
Edgewise Therapeutics lowest stock price was $14.90 and its highest was $38.12 in the past 12 months.
What is Edgewise Therapeutics’s market cap?
Edgewise Therapeutics’s market cap is $2.25B.
When is Edgewise Therapeutics’s upcoming earnings report date?
Edgewise Therapeutics’s upcoming earnings report date is May 08, 2025 which is in 44 days.
How were Edgewise Therapeutics’s earnings last quarter?
Edgewise Therapeutics released its earnings results on Mar 03, 2025. The company reported -$0.42 earnings per share for the quarter, missing the consensus estimate of -$0.417 by -$0.003.
Is Edgewise Therapeutics overvalued?
According to Wall Street analysts Edgewise Therapeutics’s price is currently Undervalued.
Does Edgewise Therapeutics pay dividends?
Edgewise Therapeutics does not currently pay dividends.
What is Edgewise Therapeutics’s EPS estimate?
Edgewise Therapeutics’s EPS estimate is -0.43.
How many shares outstanding does Edgewise Therapeutics have?
Edgewise Therapeutics has 95,205,284 shares outstanding.
What happened to Edgewise Therapeutics’s price movement after its last earnings report?
Edgewise Therapeutics reported an EPS of -$0.42 in its last earnings report, missing expectations of -$0.417. Following the earnings report the stock price went down -2.446%.
Which hedge fund is a major shareholder of Edgewise Therapeutics?
Currently, no hedge funds are holding shares in EWTX
---
Edgewise Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$47.13 (99.62% Upside)
$47.13 (99.62% Upside)
Blogger Sentiment
Bullish
EWTX Sentiment 80%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 228.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 8.6%
Last 30 Days ▼ 8.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.78%
12-Months-Change
Fundamentals
Return on Equity
-34.40%
Trailing 12-Months
Asset Growth
43.17%
Trailing 12-Months
Company Description
Edgewise Therapeutics
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
---
EWTX Stock 12 Month Forecast
Average Price Target
$47.13
▲(99.62% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Sarepta Therapeutics
―
PTC Therapeutics
―
Ultragenyx Pharmaceutical
―
Avidity Biosciences
―
Best Analysts Covering EWTX
1 Year
1 Year Success Rate
9/14 ratings generated profit
1 Year Average Return
+101.40%
reiterated a buy rating 12 days ago
Copying Laura Chico's trades and holding each position for 1 Year would result in 64.29% of your transactions generating a profit, with an average return of +101.40% per trade.
---